Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

$10m series B sees EyeGate advance drug-delivery programmes:

This article was originally published in Clinica

  • News

Executive Summary

Ophthalmic drug delivery company EyeGate Pharma has raised $10m in a series B financing led by two Paris, France-based investors Innoven Partenaires and Ventech. This brings the total investment received by EyeGate to $14m.The round will be kept open for potential US investors, says the Waltham, Massachusetts company. The firm, which is using iontophoresis technology to noninvasively deliver drugs for ocular diseases, intends to use the proceeds to begin human clinical trials in 2007 for its two lead programmes. The first programme focuses on severe uveitis and the second on glaucoma.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

See All
UsernamePublicRestriction

Register

MT053388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By